Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)

PLYMOUTH MEETING, Pa., March 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced that Dr. J.

INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference

This vaccine laggard suffered a new setback -- but there is one piece of good news.

Could Inovio Win On This 1 Vaccine Detail?

The company's Q4 results didn't provide a lot of fuel for optimism.

Why Inovio Stock Tumbled on a Good Day for the Market Wednesday

Tucked in the Q4 earnings release, Inovio Pharmaceuticals Inc (NASDAQ: INO) has paused enrollment for an ongoing INNOVATE Phase 3 trial of its lead COVID-19 vaccine candidate. The decision follows as the shot showed significantly lower antibody levels against the omicron variant.

Lab Study Shows Inovio's COVID-19 Vaccine Candidate Weaker Against Omicron Variant

Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates

PLYMOUTH MEETING, Pa., March 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and year ended December 31, 2021.

INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results

bluebird bio

These companies have taken a beating, and there's no relief on the horizon.

2 Money-Burning Biotech Stocks to Avoid

PLYMOUTH MEETING, Pa., Feb. 15, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022.

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

Could Inovio Pharmaceuticals Become the Next Moderna?

Cronos Group

These companies wouldn't be worth a second look, even in a less volatile market.

2 Stocks to Avoid Like the Plague in 2022

Inovio's stock price is back near pre-Covid levels. It is nearing commercialization of its HPV dysplasia vaccines. It might even still succeed in the Covid vaccine game.

Inovio Undervalued On Potential 2022 Catalyst

Inovio (INO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Inovio (INO) Looks Ripe for Bottom Fishing

Following the recent pullback in Inovio Pharmaceuticals Inc.'s (NASDAQ:INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities. The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio Pharmaceuticals from Underperform to Neutral while raising the price target from $8 to $10.

Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals

The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

Ocugen, Inc.

Both companies could become notable latecomers in the coronavirus vaccine market.

Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month, while it is down 8% over the last week. This can be attributed to the spread of the new Covid-19.

Is A Rise Imminent For Inovio Pharmaceuticals Stock After A Large 17% Fall In A Month

Nikola

SNDL Inc.

Jaw-dropping sales growth doesn't always tell investors the full story.

3 Ultra-Popular Stocks Expected to Increase Sales 981% to 5,569% in 2022

PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety data in participants from REVEAL1, completing enrollment in REVEAL2, and advancing its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN.

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

Dynavax Technologies

Novavax

These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant.

Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week

Pinterest

One of these stocks is poised to rebound, but the other still looks very risky.

2 Stocks That Are Down 60% (or More) From Their 52-Week Highs

Inovio plans to tackle the omicron variant.

Is Inovio Stock Set to Rebound?

PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern.

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

Both vaccine makers still have big hurdles to jump.

News for Inovio Pharmaceuticals Stock (INO)